Neuromuscular blocking agents: Difference between revisions

(Created page with "==Background== These drugs fall into two groups: *'''Non-depolarizing blocking agents''': These agents constitute the majority of the clinically relevant neuromuscular blocke...")
 
No edit summary
Line 6: Line 6:
*'''Depolarizing blocking agents''': These agents act by [[Depolarization|depolarizing]] the [[sarcolemma]] of the skeletal [[muscle fiber]]. This persistent depolarization makes the muscle fiber resistant to further stimulation by ACh.
*'''Depolarizing blocking agents''': These agents act by [[Depolarization|depolarizing]] the [[sarcolemma]] of the skeletal [[muscle fiber]]. This persistent depolarization makes the muscle fiber resistant to further stimulation by ACh.


==Types==
{| class="wikitable"
{| class="wikitable"
|+Neuromuscular Blocking Agents
|+Neuromuscular Blocking Agents
Line 20: Line 21:
|
|
|
|
|-
|[[Rapacuronium]] (Raplon)
|
|
|
|
|-
|[[Mivacurium]] (Mivacron)
|90
|12–18<ref name=Rang151/>
|
*[[hypotension]] (transiently), by release of histamine<ref name=Rang151/>
|No longer manufactured secondary to marketing, manufacturing, and financial concerns
|refrigerated
|-
|-
|[[Atracurium]] (Tracrium)
|[[Atracurium]] (Tracrium)
Line 43: Line 30:
|widely<ref name=Rang151/>
|widely<ref name=Rang151/>
|refrigerated
|refrigerated
|-
|[[Doxacurium]] (Nuromax)
|
|long<ref name=Rang151/>
|
*[[hypotension]], transiently,<ref name=Rang151/> by release of histamine
*Toxic metabolite called [[laudanosine]], greater accumulation in individuals with renal failure
|
|
|-
|-
|[[Cisatracurium]] (Nimbex)
|[[Cisatracurium]] (Nimbex)
Line 83: Line 61:
|non-refrigerated
|non-refrigerated
|-
|-
|[[Tubocurarine]] (Jexin)
|300 or more<ref name=Rang151>{{cite book |author=Rang, H. P. |title=Pharmacology |publisher=Churchill Livingstone |location=Edinburgh |year=2003 |pages= |isbn=0-443-07145-4 |oclc= 51622037|doi=}} Page 151</ref>
|60–120<ref name=Rang151/>
|
*[[hypotension]] (by [[ganglion-block]] and histamine release)<ref name=Rang151/>
*[[Bronchoconstriction]] (by histamine release)<ref name=Rang151/>
|rarely<ref name=Rang151/>
|
|-
|[[gallamine]] (Flaxedil)
|300 or more<ref name=Rang151/>
|60–120<ref name=Rang151/>
|
*[[tachycardia]]
|
|
|-
|[[Pipecuronium]]
|90
|180 or more{{Citation needed|date=March 2010}}
|
*[[tachycardia]] (slight)<ref name=Rang151/>
(no hypotension)<ref name=Rang151/>
|
|non-refrigerated
|}
|}


Line 114: Line 67:
* Non-depolarizing blockers are reversed by [[acetylcholinesterase inhibitor]] drugs since they are competitive antagonists at the ACh receptor so can be reversed by increases in ACh.
* Non-depolarizing blockers are reversed by [[acetylcholinesterase inhibitor]] drugs since they are competitive antagonists at the ACh receptor so can be reversed by increases in ACh.
* The depolarizing blockers already have ACh-like actions, so these agents have prolonged effect under the influence of acetylcholinesterase inhibitors. Administration of depolarizing blockers initially produces ''fasciculations'' (a sudden twitch just before paralysis occurs). This is due to depolarization of the muscle. Also, post-operative pain is associated with depolarizing blockers.
* The depolarizing blockers already have ACh-like actions, so these agents have prolonged effect under the influence of acetylcholinesterase inhibitors. Administration of depolarizing blockers initially produces ''fasciculations'' (a sudden twitch just before paralysis occurs). This is due to depolarization of the muscle. Also, post-operative pain is associated with depolarizing blockers.
==Sources==
<references/>

Revision as of 03:22, 24 February 2015

Background

These drugs fall into two groups:

  • Non-depolarizing blocking agents: These agents constitute the majority of the clinically relevant neuromuscular blockers. They act by competitively blocking the binding of ACh to its receptors, and in some cases, they also directly block the ionotropic activity of the ACh receptors.[1]
  • Depolarizing blocking agents: These agents act by depolarizing the sarcolemma of the skeletal muscle fiber. This persistent depolarization makes the muscle fiber resistant to further stimulation by ACh.

Types

Neuromuscular Blocking Agents
Agent Time to onset
(seconds)
Duration
(minutes)
Side effects Clinical use Storage
Succinylcholine
Atracurium (Tracrium) 90 30 min or less[2]
  • hypotension, transiently,[2] by release of histamine
  • Toxic metabolite called laudanosine, greater accumulation in individuals with renal failure
widely[2] refrigerated
Cisatracurium (Nimbex) 90 60–80 does not cause release of histamine refrigerated
Vecuronium (Norcuron) 60 30–40[2] Few,[2] may cause prolonged paralysis[2] and promote muscarinic block widely[2] non-refrigerated
Rocuronium (Zemuron) 75 45–70[citation needed] may promote muscarinic block non-refrigerated
Pancuronium (Pavulon) 90 180 or more[citation needed]

(no hypotension)[2]

widely[2] non-refrigerated

Comparison of Drugs

The main difference is in the reversal of these two types of neuromuscular-blocking drugs.

  • Non-depolarizing blockers are reversed by acetylcholinesterase inhibitor drugs since they are competitive antagonists at the ACh receptor so can be reversed by increases in ACh.
  • The depolarizing blockers already have ACh-like actions, so these agents have prolonged effect under the influence of acetylcholinesterase inhibitors. Administration of depolarizing blockers initially produces fasciculations (a sudden twitch just before paralysis occurs). This is due to depolarization of the muscle. Also, post-operative pain is associated with depolarizing blockers.

Sources

  1. Template:Cite journal
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Cite error: Invalid <ref> tag; no text was provided for refs named Rang151